Medical experts describe unmet needs in the treatment of patients with multiple myeloma, describing challenges related to access to care and extramedullary disease.
Carol Ann Huff, MD discusses how the approval of additional bispecific antibodies for multiple myeloma might change the treatment selection process, highlighting considerations for sequencing of agents and combination therapy.